348 related articles for article (PubMed ID: 22318201)
1. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?
Hasselbalch HC
Blood; 2012 Apr; 119(14):3219-25. PubMed ID: 22318201
[TBL] [Abstract][Full Text] [Related]
2. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?
Hasselbalch HC
Leuk Res; 2013 Feb; 37(2):214-20. PubMed ID: 23174192
[TBL] [Abstract][Full Text] [Related]
3. The platelet-cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis?
Hasselbalch HC
Leuk Res; 2014 Oct; 38(10):1230-6. PubMed ID: 25149709
[TBL] [Abstract][Full Text] [Related]
4. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Sankar K; Stein BL; Rampal RK
Cancer Treat Res; 2019; 179():159-178. PubMed ID: 31317487
[TBL] [Abstract][Full Text] [Related]
5. MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives.
Hasselbalch HC; Bjørn ME
Mediators Inflamm; 2015; 2015():102476. PubMed ID: 26604428
[TBL] [Abstract][Full Text] [Related]
6. A role of NF-E2 in chronic inflammation and clonal evolution in essential thrombocythemia, polycythemia vera and myelofibrosis?
Hasselbalch HC
Leuk Res; 2014 Feb; 38(2):263-6. PubMed ID: 23932394
[TBL] [Abstract][Full Text] [Related]
7. The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis.
Masarova L; Verstovsek S
Clin Adv Hematol Oncol; 2019 May; 17(5):299-307. PubMed ID: 31188809
[TBL] [Abstract][Full Text] [Related]
8. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms.
Skov V; Thomassen M; Kjær L; Ellervik C; Larsen MK; Knudsen TA; Kruse TA; Hasselbalch HC
PLoS One; 2022; 17(6):e0270669. PubMed ID: 35771847
[TBL] [Abstract][Full Text] [Related]
10. Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.
Mora B; Giorgino T; Guglielmelli P; Rumi E; Maffioli M; Rambaldi A; Caramella M; Komrokji R; Gotlib J; Kiladjian JJ; Cervantes F; Devos T; Palandri F; De Stefano V; Ruggeri M; Silver RT; Benevolo G; Albano F; Cavalloni C; Barraco D; Pietra D; Barbui T; Rotunno G; Vannucchi AM; Passamonti F
Leuk Res; 2018 Jun; 69():100-102. PubMed ID: 29734070
[No Abstract] [Full Text] [Related]
11. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Hasselbalch HC; Holmström MO
Semin Immunopathol; 2019 Jan; 41(1):5-19. PubMed ID: 30203226
[TBL] [Abstract][Full Text] [Related]
12. Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development.
Andersen M; Sajid Z; Pedersen RK; Gudmand-Hoeyer J; Ellervik C; Skov V; Kjær L; Pallisgaard N; Kruse TA; Thomassen M; Troelsen J; Hasselbalch HC; Ottesen JT
PLoS One; 2017; 12(8):e0183620. PubMed ID: 28859112
[TBL] [Abstract][Full Text] [Related]
13. Predictive Value of Kozak Gene Polymorphism for Thrombosis in Patients with Philadelphia-Negative MPNs.
El-Ghonemy MS; El-Ashwah S; Denewer M; Soliman EA; El-Baiomy M; Elkerdawy H; El-Sebaie A
Asian Pac J Cancer Prev; 2021 Apr; 22(4):1195-1201. PubMed ID: 33906312
[TBL] [Abstract][Full Text] [Related]
14. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
Björkholm M; Hultcrantz M; Derolf ÅR
Best Pract Res Clin Haematol; 2014 Jun; 27(2):141-53. PubMed ID: 25189725
[TBL] [Abstract][Full Text] [Related]
15. A Novel Morphological Parameter Predicting Fibrotic Evolution in Myeloproliferative Neoplasms: New Evidence and Molecular Insights.
Fiorentino V; Tralongo P; Martini M; Betti S; Rossi E; Pierconti F; De Stefano V; Larocca LM
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887218
[TBL] [Abstract][Full Text] [Related]
16. Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms.
Hasselbalch HC
Expert Rev Hematol; 2014 Apr; 7(2):203-16. PubMed ID: 24524202
[TBL] [Abstract][Full Text] [Related]
17. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis.
Anderson JE; Sale G; Appelbaum FR; Chauncey TR; Storb R
Br J Haematol; 1997 Sep; 98(4):1010-6. PubMed ID: 9326205
[TBL] [Abstract][Full Text] [Related]
19. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Passamonti F
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S25-7. PubMed ID: 22035744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]